1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Hematological Malignancies: Multiple Myeloma (MM) – Early and Robust Diagnosis along with New Treatment Options can have Considerable Impact on Management of the Disease

While targeting unmet needs in the treatment of hematological malignancies/ cancer through innovative drug development strategies have witnessed favorable outcomes, the specific choice of the therapies is dependent on the identification of important genomic alterations in cancerous cells that allow for the tumor’s sub classification. Over the past decade, Proteasome inhibitor and the immunomodulatory drugs have become the cornerstone of treatment for pts with Multiple Myeloma (MM) resulting in improved survival. However, eventually all pts relapse and use of modern diagnosis will enable risk stratification to help distinguish pts along the spectrum of the condition.

This can aid in the selection of new treatment options for Relapsed/ Refractory Multiple Myeloma (RRMM) to further improve survival and quality of life of each patient. Two new drugs have successfully fulfilled this need – POMALYST/ IMNOVID (pomalidomide – POM, Celgene, approved) and Kyprolis (carfilzomib-CFZ, Amgen/ Ono Pharma – JP, approved). While novel targets address unmet need, the pertinent Question remains – is there a need for further improvement? What should be the diagnosis criteria and/or novel imaging / diagnostic tools that can further stratify a pts’ risk profile?

Precision medicine approaches in myeloma require fast, robust, and practicable molecular diagnostic tools, and the current diagnostic standard iFISH (interphase fluorescence in situ hybridization) is unable to fulfill any of these criteria. Integration of Diagnostics into therapeutic products/ industry has potential to improve trial design, enhance safety profile, enhance therapeutic efficacy, accelerate trial outcome, and increase commercial success. However, there are few hurdles which are also associated with new model, such as understanding the diagnostic industry, complex trial execution, seeking a ‘right’ diagnostic partner, managing the co-development process, regulatory uncertainty around companion diagnostics and intellectual property issues.

Table Of Contents

Hematological Malignancies: Multiple Myeloma (MM) - Early and Robust Diagnosis along with New Treatment Options can have Considerable Impact on Management of the Disease
1. Executive Summary
2. Disease Overview, Diagnosis, and Current Treatment
2.1 Overview of Diagnostic tools for Multiple Myeloma
2.2 Diagnostic Criteria of Myeloma and Recent Amendment
2.3 Diagnostic Approaches for Multiple Myeloma
2.3.1 Molecular pathogenesis of Myeloma
2.3.2 Unmet Need
2.3.3 New Diagnostics Perspective and Technologies
a ‘Companion' Diagnostics (CDx)
b Genome-wide array
c RAN based technologies
d Next-Generation Sequencing (NGS) technology
3. Diagnostic Tools for Multiple Myeloma
3.1 Affymetrix GeneChip
3.2 SkylineDx MMprofiler
3.3 AgenaBio iPLEX Genotyping
3.4 Signal Genetics MyPRS
3.5 Cancer Genetics Genomic Products
3.6 Illumina NGS
3.7 NeoGenomics CLIA-certified Cancer Test
3.8 Exiqon microRNA PCR
3.9 Regulus Therapeutics microRNA Marker
3.10 Rosetta Genomics Cancer Origin Test
3.11 Sequenta LymphoSIGHT Platform
4. MandA Deals and Market Opportunity in Diagnostic Space
5. Current Therapies
5.1 Newly Diagnosed Multiple Myeloma (NDMM)
5.1.1 Competitive Landscape for NDMM
5.2 Relapsed and/or Refractory Multiple Myeloma (RRMM)
5.2.1 Competitive Landscape for RRMM
5.3 Approved Therapies
5.3.1 Revlimid
5.3.2 Velcade
5.3.1 Kyprolis
5.1 Data Comparison
5.4.1 Newly Diagnosed Multiple Myeloma (NDMM)
5.4.2 Relapsed and/or Refractory Multiple Myeloma (RRMM)
1. Novel Targets
6.1 Monoclonal Antibodies
6.1.1 Elotuzumab
6.1.2 Situximab
6.1.3 Daratumumab
6.1.4 MOR202
6.1.5 SAR650984
6.1.6 BI-505
6.1.7 BHQ880
6.1.8 CT-011
6.1.9 IPH2101/ Lirilumab
6.1.10 BMS-936564 (ulocuplumab)
6.2 Small Molecules
6.2.1 Panobinostat
6.2.2 Ixazomib (MLN9708)
6.2.3 Aplidin (plitidepsin)
6.2.4 ARRY-520 (filanesib)
6.2.5 Oprozomib
6.2.6 KPT-330 (selinexor)
6.2.7 SNS01-T
6.2.8 Ibrutinib
6.2.9 Ricolinostat
6.2.10 Afuresertib
6.2.11 KW-2478
6.2.12 BT-062
2. Clinical Milestones
3. Launch Timeline and Commercial Opportunity of Late-Stage Pipeline
4. MandA/ Licensing Deals and Unpartnered Product Opportunities

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 10125
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Drugs and Diagnostics for Hematological Disorders: Global Markets

Drugs and Diagnostics for Hematological Disorders: Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Receive detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. - Learn about the types of diagnostic and treatment ...

Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in the US

  • October 2016
  • Pathology  

    Autoimmune Dise...  

  • United States  

View report >

Digestive System Disorder Statistics in the US

  • October 2016
    11 pages
  • Digestive Syste...  

  • United States  

    United Kingdom  

    North America  

View report >

Cancer Statistics in the US

  • October 2016
    10 pages
  • Cancer  


  • United States  

View report >


Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.